By: Ma. Imee Lynne C. Esquibel, MD

A typical Saturday at Jollibee  Dapitan, where Dr. Leonid  Zamora gave a lecture on stratifying lupus patients on the molecular level. It was indeed a fruitful morning spearheaded by no less than the section chairman of UST Hospital Section of Rheumatology Dr. Sandra V. Navarra and attended by several consultants and trainees. We have consultants with us, Dr. Charmaine “Meng” Roberto an alumnus of the UST fellowship training program in Rheumatology and is currently the training officer at Jose Reyes Memorial Medical Center, and Dr. Sheila Leynes also an alumnus and  a visiting consultant at USTH. Fellows and pre-fellows from St. Luke’s Medical Center graced us with their presence – Noreen Kintanar, Ronald Ramirez, Mardi Bañez and Kate Chua. And fellows from Jose Reyes also arrived – Michelle de Jesus and Miguela Suarez. The USTH medical residents  also came to attend the lecture – Nenuel Luna, Fatima Gutierrez and Jaja Jorge

 It was an interesting lecture that emphasized on the importance of the research studies in patients with systemic lupus erythematosus (SLE). Some concepts of research were differentiated like the basic science research where it is the typical studies done in laboratories or the “test tube research” as we know it. We also have the translational research and clinical research which involves human as subjects and has been widely used in improving the patients general health and even finding cure to their illness. There were also made mentioned of studies that are currently being pursued at the molecular level. Genomics for instance pertains to analysis of the DNA of living beings, whereas transcriptomics is a study of RNA being transcribed from the DNA. It was such a refreshing and an informative lecture focusing on the genetics level of lupus.

 The highlight of the talk was a research done by Dr. Virginia Pascual. It was a study on 158 pediatric patients with SLE wherein there was genetic profiling and stratification done in terms of demographic, treatment received, disease activity and nephrtis classification. The study found out that there was a prevalence of interferon (IFN) and plasmablast signatures making it a robust biomarker for disease activity in SLE. In addition, there were also increased neutrophil transcripts during progression to active nephritis. This study somehow explains why some clinical trials fail due to molecular heterogeneity of SLE. Furthermore, this can be an eye opener and a guide for those who will try to develop clinical trials for new treatment regimens in patients with SLE. For the fellows in training, this could be an interesting study to pursue that could be of great help in our lupus patients, especially that there were no Asians included on the study of Dr. Pascual. Somehow having such study with data on Filipino people would guide the rheumatologists in choosing a better treatment regimen for SLE patients having disease activity flares.